Compound ID | 7

Update compound information

MEDI3902

Synonym(s): Gremubamab

Class: Antibody

Agent Type: Indirect acting; Antivirulence; Antibody;
Spectrum of activity: Gram-negative
Mechanism of action: Targets the type 3 secretion (T3S) protein PcrV and Psl exopolysaccharide
Target Pathogen: Active against Pseudomonas aeruginosa causing nosocomial pneumonia
Institute where first reported: Medimmune, USA
Year first mentioned: 2014
Highest developmental phase: Phase 2 (NCT04631016)
Development status: Active
External links:
PubChem link: https://pubchem.ncbi.nlm.nih.gov/substance/377483940
Guide to Pharmacology: gremubamab
Citations:
  • https://aac.asm.org/content/63/8/e00710-19
  • https://clinicaltrials.gov/ct2/show/NCT02255760?term=medi3902&rank=1
  • https://www.astrazeneca.com/media-centre/press-releases/2014/medimmune-fda-medi3902-nosocomial-pneumonia-prevention-23092014.html#
  • https://www.medimmune.com/research/pipeline

    • AntibioticDB is supported by GARDP.

    If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

    The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.